Vancomycin as an Antibacterial Agent Capped with Silver Nanoparticles: An Experimental Potential Analysis.

Area of Science:

• Nanotechnology
• Microbiology
• Infectious Diseases

Background:

• Antibiotic resistance is a growing global health threat, with Methicillin-resistant Staphylococcus aureus (MRSA) being a critical concern.
• Vancomycin is a key antibiotic for treating MRSA infections, but resistance is emerging.
• Silver nanoparticles (AgNPs) possess broad-spectrum antimicrobial activity and are explored as adjunct therapies.

Purpose of the Study:

• To enhance the antibacterial efficacy of vancomycin against Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria.
• To develop a novel nanodrug complex by functionalizing silver nanoparticles with vancomycin.
• To investigate the synergistic antibacterial effects of the vancomycin-functionalized silver nanoparticles (Van@AgNPs).

Main Methods:

• Silver nanoparticles (AgNPs) were synthesized using a chemical reduction method with silver nitrate and trisodium citrate.
• Synthesized AgNPs were functionalized with vancomycin to create the Van@AgNPs nanodrug complex.
• The agar well diffusion technique was employed to evaluate the synergistic antibacterial activity of Van@AgNPs against Staphylococcus aureus and Escherichia coli.

Main Results:

• The synthesized silver nanoparticles demonstrated broad-spectrum antibacterial activity.
• The Van@AgNPs complex exhibited significantly enhanced antibacterial potency against both Gram-positive and Gram-negative bacteria compared to vancomycin alone.
• The observed enhancement in antibacterial activity was synergistic, indicating a combined effect greater than the sum of individual components.

Conclusions:

• The developed Van@AgNPs nanodrug complex shows promising synergistic antibacterial activity, offering a potential strategy to combat antibiotic-resistant bacteria.
• Functionalizing silver nanoparticles with vancomycin can overcome existing resistance mechanisms and improve treatment outcomes for bacterial infections.
• This approach holds potential for developing next-generation antimicrobial therapies against challenging pathogens like MRSA.